These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10910310)

  • 21. The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: a literature review.
    Prasad M; Rentz AM; Revicki DA
    Pharmacoeconomics; 2003; 21(11):769-90. PubMed ID: 12859219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study.
    van Zyl JH; de K Grundling H; van Rensburg CJ; Retief FJ; O'Keefe SJ; Theron I; Fischer R; Bethke T
    Eur J Gastroenterol Hepatol; 2000 Feb; 12(2):197-202. PubMed ID: 10741935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies.
    Howden CW; Henning JM; Huang B; Lukasik N; Freston JW
    Am J Gastroenterol; 2001 Jun; 96(6):1704-10. PubMed ID: 11419818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.
    Canani RB; Cirillo P; Roggero P; Romano C; Malamisura B; Terrin G; Passariello A; Manguso F; Morelli L; Guarino A;
    Pediatrics; 2006 May; 117(5):e817-20. PubMed ID: 16651285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group.
    Sonnenberg A; Schwartz JS; Cutler AF; Vakil N; Bloom BS
    Arch Intern Med; 1998 Apr; 158(8):852-60. PubMed ID: 9570170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to 'standard doses' of H2-receptor antagonists.
    Lundell L; Backman L; Ekström P; Enander LH; Fausa O; Lind T; Lönroth H; Sandmark S; Sandzén B; Unge P
    Aliment Pharmacol Ther; 1990 Apr; 4(2):145-55. PubMed ID: 1983321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison of the cost-efficacy ratio of omeprazole and ranitidine in the treatment of reflux esophagitis].
    Bergmann JF; Hamelin B; Barbier JP
    Gastroenterol Clin Biol; 1995 May; 19(5):482-6. PubMed ID: 7589999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
    Lucas LM; Gerrity MS; Anderson T
    Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy.
    Peters FT; Kuipers EJ; Ganesh S; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
    Aliment Pharmacol Ther; 1999 Jul; 13(7):921-6. PubMed ID: 10383527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.
    Richter JE; Peura D; Benjamin SB; Joelsson B; Whipple J
    Arch Intern Med; 2000 Jun; 160(12):1810-6. PubMed ID: 10871975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland.
    Viljakka M; Nevalainen J; Isolauri J
    Scand J Gastroenterol; 1997 Aug; 32(8):766-72. PubMed ID: 9282967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
    Spechler SJ; Hunter JG; Jones KM; Lee R; Smith BR; Mashimo H; Sanchez VM; Dunbar KB; Pham TH; Murthy UK; Kim T; Jackson CS; Wallen JM; von Rosenvinge EC; Pearl JP; Laine L; Kim AW; Kaz AM; Tatum RP; Gellad ZF; Lagoo-Deenadayalan S; Rubenstein JH; Ghaferi AA; Lo WK; Fernando RS; Chan BS; Paski SC; Provenzale D; Castell DO; Lieberman D; Souza RF; Chey WD; Warren SR; Davis-Karim A; Melton SD; Genta RM; Serpi T; Biswas K; Huang GD
    N Engl J Med; 2019 Oct; 381(16):1513-1523. PubMed ID: 31618539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial).
    Waghray A; Waghray N; Perzynski AT; Votruba M; Wolfe MM
    Dig Dis Sci; 2019 Jan; 64(1):158-166. PubMed ID: 30094626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cost-utility analysis comparing omeprazole with ranitidine in the maintenance therapy of peptic esophageal stricture.
    Stal JM; Gregor JC; Preiksaitis HG; Reynolds RP
    Can J Gastroenterol; 1998; 12(1):43-9. PubMed ID: 9544411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis.
    Ofman JJ; Yamashita BD; Siddique RM; Larson LR; Willian MK
    Am J Manag Care; 2000 Aug; 6(8):905-16. PubMed ID: 11186502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.
    Galmiche JP; Barthelemy P; Hamelin B
    Aliment Pharmacol Ther; 1997 Aug; 11(4):765-73. PubMed ID: 9305487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of antisecretory treatment on respiratory symptoms of gastroesophageal reflux disease in children.
    Ummarino D; Miele E; Masi P; Tramontano A; Staiano A; Vandenplas Y
    Dis Esophagus; 2012; 25(8):671-7. PubMed ID: 22236501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis.
    Robinson M; Decktor DL; Maton PN; Sabesin S; Roufail W; Kogut D; Roberts W; McCullough A; Pardoll P; Saco L
    Aliment Pharmacol Ther; 1993 Feb; 7(1):67-73. PubMed ID: 8439639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omeprazole or ranitidine plus metoclopramide for patients with severe erosive oesophagitis. A cost-effectiveness analysis.
    Bloom BS; Hillman AL; LaMont B; Liss C; Schwartz JS; Stever GJ
    Pharmacoeconomics; 1995 Oct; 8(4):343-9. PubMed ID: 10155675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.